CNS Drugs

Article	Citations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond	160
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment	115
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies	92
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status	92
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview	81
Intranasal Insulin for Alzheimer’s Disease	79
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	67
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	65
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability	61
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome	61
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression	59
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis	58
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	54
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication	54
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys	53
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain	52
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis	52
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score	51
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders	49
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies	46
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis	43
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study	41
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis	39
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs	38
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis	38

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)	38
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status	37
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia	36
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders	35
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update	33
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment	32
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder	31
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review	31
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment	31
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies	31
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)	31
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy	30
Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke	30
Pharmacotherapy to Manage Central Post-Stroke Pain	29
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis	28
Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures	27
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience	27
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder	27
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies	26
Dextromethorphan/Bupropion: First Approval	25
Risdiplam: A Review in Spinal Muscular Atrophy	25
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively	25
Potential Role of Curcumin for the Treatment of Major Depressive Disorder	25
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study	24
COMT Inhibitors in the Management of Parkinson’s Disease	24
Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases	22
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis	22
Nusinersen: A Review in 5q Spinal Muscular Atrophy	21
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data	21
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System	20
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants	20
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis	20
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?	20
Treatment Options in Refractory Autoimmune Encephalitis	20
Opicapone: A Review in Parkinson’s Disease	19
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment	19
Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage	19
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations	19
Pharmacological Management of Apathy in Dementia	19
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention	19
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden	18
A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD)	18
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study	18
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing	18
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program	18
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis	18
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval	17
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)	17
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials	17
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine	17

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial	17
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders	16
New Oral Drugs for Migraine	15
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation	15
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study	15
Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)	14
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development	14
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use	14
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis	14
Efficacy and Safety of Ibuprofen Plus Paracetamol in a Fixed-Dose Combination for Acute Postoperative Pain in Adults: Meta-Analysis and a Trial Sequential Analysis	14
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia	14
Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study	14
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives	14
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease	14
Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?	13
Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features	13
The Options for Neuraxial Drug Administration	13
New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder	13
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research	13
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression	13
Antiseizure Drugs and Movement Disorders	13
Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled T	12
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments	12
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment	12
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio	12
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials	12
Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions	12
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use	12
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder	12
Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy	11
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophre	11
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder	11
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controll	11
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study	11
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?	11
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications	11
Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis	11
Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents	11
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in H	11
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk	11
The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies	11
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis	10
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy	10
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease	10
Pharmacotherapy for Frontotemporal Dementia	10
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia	10
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat	10
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies	10
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies	9
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review	9
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex	9
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018	9
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions	9
Pharmacological Management of Borderline Personality Disorder and Common Comorbidities	9
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology	9
The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder	9
Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain	9
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts	9
A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making	8
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies	8
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders	8
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder	8
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors	8
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records	8
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	8
Alternative Routes of Administration of Clozapine	8
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder	8
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease	8
Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review	8
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain	8
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies	7
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Op	7
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study	7
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder	7
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review	7
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research	7
Current Principles in the Management of Drug-Resistant Epilepsy	7
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study	7
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison	7
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Repo	7

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia	7
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain	7
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia	7
OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use	7
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies	7
Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients	6
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis	6
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis	6
Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis	6
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials	6
Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy	6
Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA	6
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males	6
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease	6
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study	6
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Ob	6
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases	6
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-	6
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence	5
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study	5
Daridorexant in Insomnia Disorder: A Profile of Its Use	5
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report	5
Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders	5
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine N	5
Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression	5
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model	5
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia	5
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem	5